$Histogenics Corporation(OCGN)$Covaxin成功完成了2.58万名志愿者的3期临床试验，”巴拉特生物技术公司联合董事总经理Suchitra Ella在一份声明中表示感谢主要研究人员和医护人员对公私合营疫苗计划的支持。

Covaxin successfully completes phase 3 clinical trials enrolment of 25,800 volunteers,” Suchitra Ella, Joint Managing Director of Bharat Biotech in a statement while expressing gratitude towards principal investigators and healthcare workers for their support in their public-private partnership vaccine programme.